[ad_1]
“After our unique and robust clinical trial program began in Europe and now in the United States, we look forward to moving it forward quickly with our partners at BioNTech and in consultation with regulatory authorities,” said Albert Bourla, Pfizer President and CEO. . The goal is “to bring a safe and effective vaccine to those who need it most urgently as soon as possible.”
Bourla added that the short period of time, less than four months, in which people managed to move from preclinical clinical trials to humans is exceptional. The clinical trial is part of the global development program. Treatment of the first cohort of the clinical trial in Germany was completed last week.
In anticipation of a successful clinical development program, Pfizer is working to expand production capabilities for global care.
BioNTech documents are currently gaining 6.31 percent on the Nasdaq at $ 48.91.
FRANKFURT (Dow Jones)
More news from Pfizer Inc.
Image sources: Biontech
